Complement Activation by gp160 Glycoprotein of HIV-1
- 1 March 1993
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 9 (3) , 229-233
- https://doi.org/10.1089/aid.1993.9.229
Abstract
The ability of the gp160 envelope glycoprotein of HIV-1 to activate human complement and to bind C3 fragments was investigated by incubating mammalian-derived recombinant gp 160 with seronegative serum and by quantitating the binding of C3b/iC3b to the protein using a biotinylated monoclonal antibody directed against a neoepitope expressed by cleaved human C3. Recombinant gp160 activated complement in a dose- and time-dependent fashion. Complement activation occurred through the classical pathway, independently of antibodies, and required C1q. Binding of anti-HIV IgG to rgp160 prior to exposure of the envelope glycoprotein to serum resulted in enhanced complement activation. Complexes of rgp120 with anti-HIV IgG also cleaved C3 in serum, resulting in deposition of C3b on gp120. These results provide a basis for C3-mediated facilitation of viral entry into target cells expressing receptors for fragments of human C3.Keywords
This publication has 26 references indexed in Scilit:
- Complement Receptor Type 2 Mediates Infection of the Human CD4-Negative Raji B-Cell Line with Opsonized HIVScandinavian Journal of Immunology, 1992
- Antibodies and complement enhance binding and uptake of HIV-1 by human monocytesAIDS, 1992
- Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion.The Journal of Experimental Medicine, 1991
- Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formationAIDS, 1991
- Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells.The Journal of Experimental Medicine, 1990
- Improved antigenicity of the HIV env protein by cleavage site removalProtein Engineering, Design and Selection, 1988
- ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTIONThe Lancet, 1988
- Characterization of a Monoclonal Antibody MoAb bH6 Reacting with a Neoepitope of Human C3 Expressed on C3b, iC3b, and C3cScandinavian Journal of Immunology, 1988
- The physiological breakdown of the third component of human complementMolecular Immunology, 1980
- Third component of human complement: purification from plasma and physicochemical characterizationBiochemistry, 1976